Skip to main content
. Author manuscript; available in PMC: 2013 Jun 13.
Published in final edited form as: Anesthesiol Clin. 2012 Jun 13;30(2):333–346. doi: 10.1016/j.anclin.2012.04.003

Table 3. Recommendations from the 2007 guidelines for management of severe traumatic brain injury[2-13].

Parameters Recommendations
Blood pressure
  • Monitor and avoid hypotension (Systolic Blood Pressure < 90 mmHg). (level II)

Oxygenation
  • Monitor and avoid hypoxia (PaO2 < 60 mmHg or oxygen saturation < 90%) (level III)

Hyperventilation
  • Prophylactic hyperventilation (PaCO2 ≤ 25 mmHg) is not recommended. (level II)

  • Hyperventilation is recommended as a temporizing measure for the reduction of elevated intracranial pressure. (level III)

Hyperosmolar
therapy
  • Mannitol (0.25 - 1.0 g/kg) is effective for control of raised intracranial pressure. Hypotension should be avoided. (level II)

  • Restrict mannitol use prior to intracranial pressure monitoring to patients with signs of transtentorial herniation or progressive neurological deterioration not attributable to extracranial causes. (level III)

ICP
  • ICP should be monitored in patients with severe TBI and abnormal CT scan (level II) and in patients with normal CT scan if two or more of following are present: age > 40 years, motor posturing, systolic blood pressure < 90 mmHg (level III).

  • Treatment should be initiated if intracranial pressure is > 20 mmHg (level II)

Temperature
  • Prophylactic hypothermia is not significantly associated with decreased mortality. (level III)

  • Hypothermia may have higher chances of reducing mortality when cooling is maintained for more than 48 hours. (level III)

CPP
  • Maintain cerebral perfusion pressure between 50-70 mmHg.

  • Avoid aggressive treatment with fluid and pressors to maintain CPP > 70 mmHg. (level II)

  • Avoid CPP < 50 mmHg. (level III)

Brain
Oxygenation
  • Treat when SjvO2 < 50% or brain tissue oxygen tension < 15 mmHg. (level III)

Steroids
  • In patients with moderate or severe TBI, high-dose methylprednisolone is associated with increased mortality and is contraindicated. (level I)